Isomab Ltd

IsomAb was recently featured in an article in MedNous (Evernow Publishing Ltd)!   In this article, we discuss the development of ISM-001, our isoform-specific antibody targetting VEGF-A165b which provides a novel treatment pathway for Peripheral Arterial Disease (PAD).   PAD affects over 200 million people globally, causing pain, disability, and in severe cases, limb amputation. Current treatments focus on symptom management or surgeries that are not always effective or suitable for all patients. This highlights an urgent need for therapies that target the condition's underlying cause.   ISM-001 has a unique mechanism of action. It targets VEGF-A165b, an isoform of the vascular endothelial growth factor-A (VEGF-A) protein that acts as a brake on angiogenesis—the body’s process of forming new blood vessels. In PAD patients, particularly those with diabetes and obesity, VEGF-A165b is upregulated, suppressing blood vessel growth and worsening ischemic conditions.    ISM-001 specifically neutralises VEGF-A165b, removing this inhibition and allowing the body to restore blood flow, oxygen delivery, and tissue repair in affected areas.   Our innovative approach could radically improve outcomes for PAD patients, offering hope to millions who currently face limited options. Read the full article: https://lnkd.in/gifWKHis #PeripheralArterialDisease #Antibodies

Last week, our Chief Scientific Officer and Co-Founder, Professor David Bates, delivered an inspiring talk at the British Heart Foundation’s Translational Research Day.   It was fantastic to see such an engaged and interested audience—thank you all for joining us!

Meet Professor David Bates, Chief Scientific Officer and Co-Founder of IsomAb.    As CSO and Co-Founder, Dave brings 30 years of expertise in VEGF-A isoforms and biology to IsomAb. His role involves working on the pre-clinical development programme for the development candidate ISM-001. He is also a Board Director; the Board ensures that the Company operates in line with our values and potentially generates value for our investors.    Dave holds a PhD in Physiology from the University of London, where he began studying vascular function in health and disease, leading to a career focused on VEGF-A and VEGF-C physiology. He established his first lab at the University of Leicester in 1996, later moving to Bristol to direct a multidisciplinary lab with five research groups investigating various health conditions.   In 2012, he became Head of Preclinical Oncology at the University of Nottingham, launching a university-wide cancer centre in 2017. In 2013, he co-launched a spin-out company, Exonate, to develop inhibitors for a splice factor kinase affecting VEGF splicing. Serving as CSO, until 2022, he was part of a team leading the development of Exonate’s clinical candidate into a successful phase I clinical trial.    Outside of work, Dave is a keen backcountry skier and qualified ski guide for the Austrian Alpine Club, leading multi-day ski tours through high alpine terrain and climbing peaks. He’s also a keen wine buff, enjoys hiking in the summer and is always working on improving his golf handicap!    Dave is giving a talk at the British Heart Foundation’s Translational Research Day on 21 November, from 11:40 am to 12:00 pm. He’ll be presenting in the session 'Innovation to Impact: Success Stories, Lessons Learned, and Future Outlook,' focusing on novel therapeutics and drug discovery. Don’t miss it if you’re attending! Learn more about the rest of the team, our science and our progress from our refreshed website: https://isomab.bio/

Our new website is live! We’ve come a long way since our beginnings as a spin-out from the University of Nottingham just two years ago. We have revamped our website to reflect this progression, as we develop our isoform specific antibodies for Peripheral Arterial Disease and beyond. Check out our new look and find out more about us on our new website: https://isomab.bio/

PRESS RELEASE: IsomAb Announces Strategic Collaboration with Catalent   We are delighted to announce our new partnership with Catalent Pharma Solutions, a leader in biologics development and manufacturing. Catalent will support the development of our therapeutic antibody, ISM-001, from initial process development right through to clinical trial supply.   ISM-001 is designed to neutralise the anti-angiogenic VEGF-A splice isoform VEGF-A165b. This treatment is initially aimed at patients with type 2 diabetes and peripheral artery disease (PAD) who experience chronic limb-threatening ischaemia (CLTI). PAD impacts over 230 million people worldwide and those with CLTI face the risk of amputation due to limited treatment options.   With the added expertise and support from Catalent, we aim to drive forward the development of ISM-001 to address this critical unmet need, providing new hope for patients globally.   Read the full release: https://lnkd.in/gKZeGjec

📣 NEW PRESS RELEASE: IsomAb Announces Nomination of Development Candidate for Peripheral Arterial Disease and Strategic Collaboration with Pfizer    We’re delighted to share that we have nominated ISM-001 as a development candidate for peripheral arterial disease (PAD). ISM-001 is a potential first-in-class, therapeutic antibody designed to neutralise VEGF-A165b, the anti-angiogenic VEGF-A splice isoform which acts as a brake on development of new blood vessels leading to chronic limb threatening ischaemia (CLTI). ISM-001 is being advanced into a program of pre-clinical studies necessary for gaining approval to enter first-in-human clinical trials.   We’re also excited to announce a strategic collaboration with Pfizer Ignite to accelerate preclinical and IND-enabling studies for ISM-001.    Our CEO, Jackie Turnbull, said: “Today’s announcement represents an important milestone for IsomAb and we continue to be encouraged by the potential of ISM-001 as a first-in-class treatment for patients with PAD, especially type 2 diabetics with CTLI at high risk of amputation. We appreciate the devastating loss of losing a limb and the impact on the lives of patients who have very limited treatment options. Given Pfizer’s strong commitment, extensive capabilities and deep expertise in developing new therapeutics, we are proud to partner with them to support the development of ISM-001, a transformative treatment for patients with PAD. We look forward to realising the full potential of ISM-001.” Read the full release: https://lnkd.in/grUzYW-y

Great news from one of our investors - their investment in Isomab Ltd was indeed an excellent “small deal”!

This month is #PADAwarenessMonth.   Peripheral artery disease (PAD) is a vascular condition where a build-up of fatty deposits in the arteries restricts blood flow to the limbs, particularly the legs. This reduced circulation and the lack of compensating blood vessels, collaterals, causes tissue deterioration that can lead to pain, mobility issues and ulcers, which if not treated lead to amputation.   PAD is estimated to affect at least 200 million people worldwide, but despite its prevalence, there are no drugs that address the underlying cause of the disease. Current treatment options include medications to manage risk factors, or surgery to remove arterial blockages, although these are not always successful and are not suitable for all patients.   PAD, particularly in patients with type 2 diabetes (T2D), is a key focus of the work we do at IsomAb. We discovered that in PAD patients with T2D, the process in which new blood vessels are formed to bypass blocked arteries is inhibited by abnormally high levels of an anti-angiogenesis protein called VEGF-A165b.    This discovery is opening up a new treatment pathway for patients and led to our development candidate, ISM-001 – a neutralising antibody that specifically targets VEGF-A165b, enabling the restoration of blood flow to affected tissues.   Find out more about our work in PAD: https://www.isomab.bio/ 

Congratulations to your daughter on signing with Manchester City Women under-12s. Dami Aboyeji We wish her all the best this season and in the future. Well done to her getting through the trial stages . Kindly follow her football journey @oliviatekkers on Instagram.

https://lnkd.in/gvwK_K5R